Ernexa Therapeutics Inc.
NCM: ERNALive Quote
About Ernexa Therapeutics Inc.
Healthcare
Biotechnology
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
📊 Fundamental Analysis
Ernexa Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -686.7%, which indicates that capital utilization is currently under pressure.
At a current price of $0.20, ERNA currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $0.18 - $4.05).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$7.93M
Trailing P/E
--
Forward P/E
-0.02
Beta (5Y)
6.85
52W High
$4.05
52W Low
$0.18
Avg Volume
1.72M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App